NORETHINDRONE ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Norethindrone Acetate patents expire, and when can generic versions of Norethindrone Acetate launch?
Norethindrone Acetate is a drug marketed by Amneal Pharms, Aurobindo Pharma Ltd, Barr, Glenmark Pharms Ltd, Mylan Labs Ltd, Novast Labs, Barr Labs Inc, Dr Reddys Labs Sa, Mylan, Apotex, and Xiromed. and is included in twenty-nine NDAs.
The generic ingredient in NORETHINDRONE ACETATE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
Summary for NORETHINDRONE ACETATE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 29 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 62 |
| Clinical Trials: | 49 |
| Patent Applications: | 3,929 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NORETHINDRONE ACETATE |
| DailyMed Link: | NORETHINDRONE ACETATE at DailyMed |
Recent Clinical Trials for NORETHINDRONE ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Bio Genuine (Shanghai) Biotech Co., Ltd. | Phase 3 |
| University of Chicago | Phase 4 |
| Myovant Sciences GmbH | Phase 4 |
Pharmacology for NORETHINDRONE ACETATE
| Drug Class | Progestin |
